TJ Cradick

TJ Cradick

Company: Gene Editing Frontiers

Job title: Chief Technology Officer

Seminars:

Exploring How Novel Nucleases & Appropriate Animal Models Are Key to Clinical Success 4:45 pm

Understand how engineering nucleases to improve on target efficacy and decrease off target effects was crucial to speeding up pre-clinical progression Evaluate how selecting mouse models and NHPs provide appropriate models to showcase efficacy and safety Reflect on how close collaboration between R&D and pre-clinic, as well as matching gene editing technology to appropriate indications,…Read more

day: Day Two

International Considerations: Evaluating the Impact of Obtaining Data from Outside the US 1:30 pm

Explore how obtaining initial data outside the US can expedite your process of moving into a later stage clinical trial in the US Reflect on how demonstrating safety and efficacy is crucial to de-risking scaling-up manufacturing and development, and for getting investment for other programs with similar gene editing technology Understand how trials outside the…Read more

day: Day One: Preclinical & Clinical Development

Roundtable: Reviewing Clinical Strategies to Facilitate Gene Therapies for Rare Disease & Beyond 2:00 pm

Key strategies to optimize clinical trial efficiency to accelerate time and cost-effectiveness Adjust approaches to account for population sizes to enhance therapeutic efficacy and safety Discuss emerging trends and future directions to optimize clinical strategy Leverage gene editing to expand into large indications in oncology and autoimmune diseases through allogeneic CAR-T platformsRead more

day: Day One: Preclinical & Clinical Development

The Future: How Baby KJ’s Personalized CRISPR Therapy Will Facilitate Better Rare Disease Targeting 9:35 am

Following the groundbreaking work to launch the world’s first personalized CRISPR therapy to treat baby KJ, a new blueprint for rare disease treatment is forming. With the baby KJ team swiftly adapting base editing technology, rapidly co-ordinating regulatory approval and redefining clinical strategies, this session offers an unmissable insight into how this pioneering approach to…Read more

day: Pre-Conference Workshop Day

A Hanson Wade Group Company

© Copyright 2025 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.